GW Pharmaceuticals PLC (GWPH) Posts Earnings Results, Misses Estimates By $0.34 EPS
GW Pharmaceuticals PLC (NASDAQ:GWPH) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.73) by $0.34, Morningstar.com reports. The business had revenue of $3.14 million during the quarter, compared to analyst estimates of $2.10 million. GW Pharmaceuticals PLC had a negative net margin of 1,021.38% and a negative return on equity of 22.81%. During the same quarter last year, the firm posted ($0.05) EPS.
GW Pharmaceuticals PLC (GWPH) traded down 6.68% on Tuesday, reaching $107.41. 321,642 shares of the company’s stock traded hands. GW Pharmaceuticals PLC has a 52 week low of $79.62 and a 52 week high of $137.88. The stock has a 50-day moving average of $105.72 and a 200 day moving average of $113.95. The firm’s market capitalization is $2.72 billion.
TRADEMARK VIOLATION NOTICE: This piece was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/08/07/gw-pharmaceuticals-plc-gwph-announces-quarterly-earnings-results.html.
Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA acquired a new position in GW Pharmaceuticals PLC during the second quarter worth approximately $163,000. Quantitative Systematic Strategies LLC acquired a new position in GW Pharmaceuticals PLC during the second quarter worth approximately $204,000. Blair William & Co. IL acquired a new position in GW Pharmaceuticals PLC during the first quarter worth approximately $207,000. Nwam LLC acquired a new position in GW Pharmaceuticals PLC during the first quarter worth approximately $208,000. Finally, Ameriprise Financial Inc. acquired a new position in GW Pharmaceuticals PLC during the first quarter worth approximately $230,000. 75.77% of the stock is owned by hedge funds and other institutional investors.
GWPH has been the subject of a number of research reports. Maxim Group initiated coverage on shares of GW Pharmaceuticals PLC in a report on Thursday, April 20th. They issued a “buy” rating and a $135.00 price objective for the company. Cantor Fitzgerald restated a “buy” rating and issued a $208.00 price objective on shares of GW Pharmaceuticals PLC in a report on Tuesday, May 9th. TheStreet cut shares of GW Pharmaceuticals PLC from a “c-” rating to a “d+” rating in a report on Wednesday, May 10th. Zacks Investment Research cut shares of GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Monday, May 15th. Finally, BidaskClub upgraded shares of GW Pharmaceuticals PLC from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 14th. Five equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $148.16.
About GW Pharmaceuticals PLC
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.